ANAVEX LIFE SCIENCES CORP (AVXL)
Health Care · biotechnology / neurology drug development · NASDAQ
Anavex Life Sciences is a clinical-stage biotech developing oral, small-molecule sigma-1 receptor agonists to treat neurodegenerative and neurodevelopmental CNS disorders.
What ANAVEX LIFE SCIENCES CORP does
Anavex Life Sciences is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases. Its lead compound, blarcamesine (ANAVEX 2-73), is an oral sigma-1 receptor agonist currently in clinical development for Alzheimer's disease, Rett syndrome, and Fragile X syndrome. The company utilizes precision medicine and genomic biomarker analysis to identify patient populations likely to respond to its treatments.
Recent developments
Under new leadership, the company has de-prioritized non-lead pipeline assets to focus exclusively on advancing blarcamesine for Alzheimer's, Rett syndrome, and Fragile X. Recent progress includes submitting Alzheimer's clinical trial data to a newly opened IND and initiating essential ADME and DDI clinical pharmacology studies to support regulatory alignment with the FDA.
From ANAVEX LIFE SCIENCES CORP's filing of 2026-08-28.
Themes: Alzheimer's disease, Rett syndrome, Fragile X syndrome, sigma-1 receptor agonists, precision medicine, CNS therapeutics
Fundamentals
- Price$1.54 as of 2026-10-08 close
- Market cap$143M as of 2026-08-28 (share count; price 2026-10-08)
- 1-year return-84.4% 2025-10-08 close $9.85 → 2026-10-08 close $1.54
- P/En/a negative earnings
- ROE-48.9% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta1.35 as of 2026-09-03
- Last reported earnings2026-08-25 SEC EDGAR Form 8-K (Item 2.02)
How AVXL compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ANAVEX LIFE SCIENCES CORP looks technically
ANAVEX LIFE SCIENCES CORP (AVXL) is trading 53.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 244 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 18, in oversold territory (below 30). It made a new 20-day low about 2 trading days ago. It is 2.7% above its 52-week low (its lowest price of the past year).
Trend
7
| Distance from the 200-day | it is trading 53.5% below its 200-day average, the long-term trend line — a long-term downtrend | -53.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.73 | $2.73 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.31 | $3.31 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 44 calendar days ago — the swings before that are what the structure reading is measured on | 44 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 244 trading days ago — a "death cross", a bearish long-term signal | 244 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control | 41.7 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 18, in oversold territory (below 30) | 18.2 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($1.50 to $2.49) — its "stochastic" reading is 4 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 4.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 35 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $10.38 | $10.38 |
|---|---|---|
| From the 52-week high | it is 85.2% below its 52-week high (its highest price of the past year) | -85.2% |
| Above the 52-week low | it is 2.7% above its 52-week low (its lowest price of the past year) | +2.7% |
| Below the 52-week high | it is 85.2% below its highest point of the past year | 85.2% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $31.50 (set on 2021-06-28) | $31.50 |
| Given back of the 52-week move | over the past year its closes ranged ($1.53 to $9.85), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.67 to $6.94. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.1% |
| From the all-time high | it is 95.1% below its all-time high | -95.1% |
| Nearest price level | it is trading 70.3% below a resistance level at $2.62 — a price it turned at twice since 2026-03-25, most recently on 2026-05-22. Since 2024-10-08 it has 0 such levels below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +70.3% |
| All-time low | its lowest closing price on record is $0.6 (set on 2014-12-01) | $0.6 |
| Above the all-time low | it is 156.7% above its all-time low | +156.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 95% of the past ~6 months) | 95th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1507 between its high and its low — about 9.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1507 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.46 and $2.89 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.46 – $2.18 – $2.89 |
| Typical daily range (% of price) | its price moves about 9.8% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.8% |
| Stretch from the 200-day average | it is trading 11.7 daily ranges below its 200-day average price (53.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 11.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.48× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-09-17 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 13 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 47.0 percentage points (the stock lost 46.0% while the market gained 1.0%) | -47.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 46.8 percentage points (the stock lost 43.0% while the market gained 3.8%) | -46.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 65.4 percentage points (the stock lost 48.0% while the market gained 17.5%) | -65.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 99.3 percentage points (the stock lost 84.4% while the market gained 15.0%) | -99.3% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 48% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 11.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -48.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 53% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.27 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | -53.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 41% below the average price paid since it last reported on 2026-07-30 (its 8-K), so the typical buyer over that stretch is under water. That average is $2.60 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -40.8% |
Price levels it has turned at before
AVXL last closed at $1.54 on 2026-10-08. Since 2024-10-08 it has turned at 0 prices below its last close and 13 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.62 | Resistance | 70.3% above the last close | turned there twice · 2026-03-25 to 2026-05-22 |
| $2.79 | Resistance | 81.5% above the last close | turned there twice · 2026-06-22 to 2026-07-08 |
| $3.50 | Resistance | 127.1% above the last close | turned there twice · 2026-01-02 to 2026-05-04 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Near the 52-week low · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst EPS estimate for AVXL
- Consensus EPS estimate-$0.11 next reporting period, as of 2026-09-29
- Readings revised upward0% of 4 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of operating losses, no revenue, and substantial future funding requirements for R&D.","Dependency on the success of a single lead compound (blarcamesine) and the inherent risks of clinical development and regulatory approval.","Financial instability and potential listing compliance issues, including identified material weaknesses in internal controls."]
What changed in the latest 10-Q
AI-assisted comparison of AVXL's 10-Q filed 2026-08-28 against the prior one filed 2026-08-28.
Management's Discussion & Analysis (MD&A)
- Reworded:
- The newer filing refers to 'ANAVEX®2-73 (blarcamesine)' while the older filing refers to 'ANAVEX ® 2-73 (blarcamesine)' in the bullet point about plans to prioritize advancement of the lead compound.
- The page number after the risk factor bullet list is '21' in the newer filing and '22' in the older filing.
- Notes:
- Both source texts appear truncated at the same point mid-sentence ('...as well as of a neuro'), so differences beyond that point cannot be assessed.
- The newer text uses 'ANAVEX®' without a space before the registered trademark symbol and without a space before '2-73', while the older text uses 'ANAVEX ® 2-73'; only the formatting/spacing differs.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for AVXL — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding AVXL as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 11,332,652
- Reported value $29,351,569
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AVXL's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AVXL had 14,333,378 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
AVXL had 15.5% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 25.13 days to cover at the same settlement.
- Reported short interest (shares) 14,333,378
- Short interest (% of shares outstanding) 15.5%
- Prior settlement (shares) 13,898,140
- Reported change 3.13%
- Days to cover (reported) 25.13
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Biogen (BIIB)
- Eli Lilly (LLY)
- Eisai (ESALY)
- Acadia Pharmaceuticals (ACAD)
- Neurocrine Biosciences (NBIX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AVXL vs…
ANAVEX LIFE SCIENCES CORP is found in…
Frequently asked questions
What does ANAVEX LIFE SCIENCES CORP (AVXL) do?
Anavex Life Sciences is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases. Its lead compound, blarcamesine (ANAVEX 2-73), is an oral sigma-1 receptor agonist currently in clinical development for Alzheimer's disease, Rett syndrome, and Fragile X syndrome. The company utilizes precision medicine and genomic biomarker analysis to identify patient populations likely to respond to its treatments.
What sector is ANAVEX LIFE SCIENCES CORP (AVXL) in?
ANAVEX LIFE SCIENCES CORP (AVXL) is classified in the Health Care sector. Its industry is biotechnology / neurology drug development. It trades on NASDAQ.
Who are ANAVEX LIFE SCIENCES CORP's (AVXL) competitors?
Notable peers of ANAVEX LIFE SCIENCES CORP (AVXL) include Biogen, Eli Lilly, Eisai, Acadia Pharmaceuticals and Neurocrine Biosciences. This peer set is informational only — not financial advice.
Is ANAVEX LIFE SCIENCES CORP (AVXL) overbought or oversold right now?
ANAVEX LIFE SCIENCES CORP (AVXL) is currently in oversold territory (its 14-day RSI is 18, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AVXL come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.